ZVRAZevra Therapeutics, Inc.
Is the business good?
The checks split: margins widening and elite returns on assets, but thin cash backing (0.5×).
Operating profit outpaces operating cash flow, watch accruals and working capital.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
High-quality, exceptional returns on the assets themselves, not leverage. ROE 42% = margin × turnover × leverage.
Unless marked, from derived.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is ZVRA?
Zevra Therapeutics, Inc. keeps 61% of every revenue dollar as operating profit, against −77% for the median Biotechnology name.
Operating margin · Biotechnology median −77% · 12 months to Q2 2026
- Cash conversion
- 0.48×
Cash conversion · the operating profit has not turned into cash yet
- Share count, year on year
- +8.9%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 11%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −42% |
| FY2021 | 27% |
| FY2022 | −419% |
| FY2023 | −181% |
| FY2024 | −368% |
| FY2025 | −59% |
Details›
- Gross margin12 months to Q2 2026
- 95%
- Operating margin12 months to Q2 2026
- 61%
- Net margin12 months to Q2 2026
- 43%
- Free cash flow margin
- 24%
- R&D as % of revenue
- 11%
- Revenue, trailing twelve months
- $136M
- Free cash flow, trailing twelve months
- $33M
- Net income, trailing twelve months
- $58M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.